12/14
11:40 pm
nbp
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
Low
Report
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
12/11
01:23 am
nbp
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO [Yahoo! Finance]
Medium
Report
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO [Yahoo! Finance]
12/11
01:12 am
nbp
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Medium
Report
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
12/10
04:30 pm
nbp
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Medium
Report
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
12/4
07:34 am
nbp
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Low
Report
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
12/3
07:30 pm
nbp
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Medium
Report
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
11/21
12:46 am
nbp
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Medium
Report
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
11/20
08:00 pm
nbp
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Medium
Report
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
10/30
04:15 am
nbp
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Medium
Report
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
10/29
06:27 pm
nbp
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Low
Report
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries